12:13 PM EDT, 04/21/2026 (MT Newswires) -- Agenus ( AGEN ) said Tuesday it appointed BAP Pharma as the company's global partner for botensilimab plus balstilimab authorized global access programs.

These programs include France's Autorisation d'Acces Compassionnel pathway as well as paid named-patient programs in select countries outside the US. Under the arrangement, BAP Pharma will coordinate global access operations, including program requests, logistics, case coordination and related payment processing.

Financial terms related to the collaboration were not disclosed.

Shares of Agenus ( AGEN ) were down 7.7% in Tuesday trading.

Price: 4.08, Change: -0.34, Percent Change: -7.69